Clinical Trial Search

Primary: The Number of Graft Related Post-operative Complications That Require a Repeat Surgery or a Non Surgical Treatment Within 12-month Post Implantation. — 0 Participants

Primary: Length of Hospital Stay Following Fontan — 11.2; 11 days

Primary: Change in Peak Oxygen Uptake From Baseline Peak Oxygen Uptake — -2.01; -1.01 ml/kg/min

Primary: Chest Tube Drainage — 686.83; 535.50 ml/kg

Primary: Change in Peak VO2 Between Baseline and Post-inspiratory Muscle Training Measurements. — 24.0 ml/kg/min — p=0.1673

Primary: Change From Baseline in Peak Oxygen Uptake/Consumption (VO2) Up to Week 16 — -0.67; -0.16 Milliliter/kilogram/minute (mL/kg/min) — p== 0.1930

Primary: Change in Maximal VO2 From Baseline to Week 26 Using Last Observation Carried Forward (LOCF) — -0.23; -0.89 mL/kg/min — p=0.092

Primary: Hemodynamics as Characterized by Vasoactive Inotrope Score (VIS) — 11; 11.3 units

Primary: Change From Baseline in Mean Oxygen Consumption (mL/kg/Min) at 6 Weeks — 30.5; 30.5; 31.3; 31.3 mL/kg/min — p=0.73

Primary: The Change in Exercise Capacity Measured Via Maximum Oxygen Consumed During Exercise (VO2) — 39.4; 36.8; 41.2; 34.4 ml/min/kg

Primary: Changes in End Diastolic and End Systolic Volume as Measured by Standard and Advanced MRI Parameters — 3.3; 3.0; 3.0; 4.4 ml

Primary: Change in VO2 Max — 1.33; 0.745 Change in ml/kg min

Primary: Change in Pulmonary Pulsatility Index — 51.6; 57.6 Ratio — p=0.1

Primary: End-systolic Elastance — 0.85; 1.8 Ees in mmHg/ml/m2

Primary: Area Under the Curve for Ambrisentan Plasma Concentration — 7871.46 ng*hr/mL